Rani Therapeutics Holdings Inc (NAS:RANI)

$ 1.42 0 (0%) Market Cap: 47.30 Mil Enterprise Value: 53.28 Mil PE Ratio: 0 PB Ratio: 13.52 GF Score: 30/100

Q4 2023 Rani Therapeutics Holdings Inc Earnings Call Transcript
Mar 20, 2024

$3.57 (+0.56%)

Earnings
Rani Therapeutics Holdings Inc To discuss the results from its Phase 1 clinical trial of RT-111. Transcript
Feb 05, 2024
Rani Therapeutics Holdings Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Sep 28, 2023
Rani Therapeutics Holdings Inc at Jefferies Healthcare Conference Transcript
Jun 08, 2023
Rani Therapeutics Holdings Inc at H.C. Wainwright BioConnect Investor Conference Transcript
May 02, 2023
Rani Therapeutics Holdings Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 18, 2023
Q4 2022 Rani Therapeutics Holdings Inc Earnings Call Transcript
Mar 22, 2023

$5.95 (-1.00%)

Earnings
Rani Therapeutics Holdings Inc To Discuss The Topline Results From The Phase 1 Part 2 Repeat Dose Study of RT-102 Call Transcript
Dec 06, 2022
Rani Therapeutics Holdings Inc at Stifel Healthcare Conference Transcript
Nov 16, 2022
Rani Therapeutics Holdings Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 14, 2022

Rani Therapeutics Holdings Inc at Needham Healthcare Conference (Virtual) Transcript

Apr 14, 2022 / 07:45PM GMT

Release Date Price: $13 (-3.49%)

Transcript

Serge D. Belanger

Needham & Company, LLC, Research Division - Senior Analyst

Good afternoon. Welcome to Needham's Annual Healthcare Conference. I'm Serge Belanger, one of the health care analysts at Needham. And we're happy to have this afternoon for our next session, Rani Therapeutics. We have a lot of team members here. I think the CEO, Talat Imran, will give us -- will introduce his colleagues as well as give us an overview of the company. We'll then proceed to some Q&A. And for those listening online, you do have the option to submit questions through the portal. We'll be checking that as we proceed with the Q&A portion. So I'll hand it over to Talat to -- with the overview.

Talat Imran;Serge D. Belanger

Rani Therapeutics Holdings, Inc. - CEO & Director;Needham & Company, LLC, Research

Great. Thank you so much, Serge, and thank you to Needham for allowing us the opportunity to present at the conference. I'm going to pull up the deck now, and hopefully, you're able to see this. Does that look good?

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.